Last reviewed · How we verify
Unasyn (AMPICILLIN)
Unasyn (Ampicillin) is a penicillin-class antibacterial drug originally developed by Wyeth Ayerst and currently owned by Apothecon. It targets the transient receptor potential cation channel subfamily M member 4 and is used to treat various bacterial infections, including acute epiglottitis, sinusitis, and gonococcal infections. Unasyn is a small molecule with a half-life of 1.4 hours and bioavailability of 62%. It is off-patent and has multiple generic manufacturers. Key safety considerations include its potential to cause allergic reactions and interact with other medications.
At a glance
| Generic name | AMPICILLIN |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Penicillin-class Antibacterial |
| Target | Transient receptor potential cation channel subfamily M member 4 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1965 |
Approved indications
- Acute bacterial epiglottitis
- Acute bacterial sinusitis
- Acute epiglottitis
- Acute exacerbation of chronic bronchitis
- Acute gonococcal cervicitis
- Acute gonococcal endometritis
- Acute gonococcal urethritis
- Acute otitis media
- Bacterial endocarditis
- Bacterial meningitis
- Bacterial peritonitis
- Bacterial pneumonia
- Bacterial septicemia
- Bacterial urinary infection
- Bacteroides Gynecological Infections
- Bacteroides Peritonitis
- Cesarean Section Infection Prevention
- Cholangitis
- Dysentery
- E. Coli Gynecological Infections
Common side effects
- Anaphylaxis
- Anaphylactoid reactions
- Eosinophilia
- Erythema multiforme
- Exfoliative dermatitis
- Glossitis
- Leukopenia
- Laryngeal stridor
- Nausea
- Pseudomembranous colitis
- Pruritus
- Serum sicknesslike reactions
Drug interactions
- desogestrel
- ethinylestradiol
- gentamicin
- levonorgestrel
- mestranol
- netilmicin
- norelgestromin
- norethisterone
- norethynodrel
- norgestimate
- tobramycin
Key clinical trials
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |